Effect of ginkgo diterpene lactone meglumine on the quality of life in patients with acute ischemic stroke

Abstract Objective Ginkgo diterpene lactone meglumine (GDLM) could improve the functional outcome after acute ischemic stroke (AIS). This study aimed to investigate the efficacy of GDLM on the quality of life in patients with AIS in China. Methods This is a post hoc analysis of Efficacy and Safety o...

Full description

Saved in:
Bibliographic Details
Main Authors: Xue Tian, Qin Xu, Xue Xia, Yijun Zhang, Xingquan Zhao, Anxin Wang
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Health and Quality of Life Outcomes
Subjects:
Online Access:https://doi.org/10.1186/s12955-024-02315-1
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846164839003586560
author Xue Tian
Qin Xu
Xue Xia
Yijun Zhang
Xingquan Zhao
Anxin Wang
author_facet Xue Tian
Qin Xu
Xue Xia
Yijun Zhang
Xingquan Zhao
Anxin Wang
author_sort Xue Tian
collection DOAJ
description Abstract Objective Ginkgo diterpene lactone meglumine (GDLM) could improve the functional outcome after acute ischemic stroke (AIS). This study aimed to investigate the efficacy of GDLM on the quality of life in patients with AIS in China. Methods This is a post hoc analysis of Efficacy and Safety of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke trial. The quality of life was measured using the EuroQoL questionnaire, including EQ-5D and EQ visual analogue scale (EQ-VAS). The primary outcomes were changes in EQ-5D and EQ-VAS from baseline to day 14 and day 90 after randomization. Results A total of 3219 patients with completed data on outcomes were enrolled, with median age of 63 years (interquartile range, 55–70) and 2,067 (64.2%) men. GDLM was associated with a significant decrease in scores of ED-5Q components (from 0 [no problem] to 3[extreme problem]), the mean difference between GDLM and placebo group was -0.14 for mobility, -0.11 for usual activities and self-care, -0.09 for pain/discomfort, and -0.34 for anxiety/depression on day 14, respectively. Similar results were observed on day 90. Additionally, there was statistically significant difference of changes in EQ-VAS between the GDLM group and the placebo group from baseline to day 14 (mean difference, 1.70; 95% confidence interval [CI], 0.78–2.62; P = 0.0003) and to day 90 after randomization (mean difference, 3.29; 95% CI, 2.37–4.22; P < 0.001). Conclusions In this analysis of Chinese patients with AIS, GDLM could improve the 14-day and 90-day quality of life compared with the placebo. Trial registration URL: https://www.clinicaltrials.gov . Unique identifier: NCT02526225. Registration Date: 2016–02-01.
format Article
id doaj-art-cb4ab84f404b4ada886e4f50def48af8
institution Kabale University
issn 1477-7525
language English
publishDate 2024-11-01
publisher BMC
record_format Article
series Health and Quality of Life Outcomes
spelling doaj-art-cb4ab84f404b4ada886e4f50def48af82024-11-17T12:49:59ZengBMCHealth and Quality of Life Outcomes1477-75252024-11-012211810.1186/s12955-024-02315-1Effect of ginkgo diterpene lactone meglumine on the quality of life in patients with acute ischemic strokeXue Tian0Qin Xu1Xue Xia2Yijun Zhang3Xingquan Zhao4Anxin Wang5Department of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical UniversityDepartment of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical UniversityDepartment of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical UniversityDepartment of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical UniversityChina National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical UniversityDepartment of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical UniversityAbstract Objective Ginkgo diterpene lactone meglumine (GDLM) could improve the functional outcome after acute ischemic stroke (AIS). This study aimed to investigate the efficacy of GDLM on the quality of life in patients with AIS in China. Methods This is a post hoc analysis of Efficacy and Safety of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke trial. The quality of life was measured using the EuroQoL questionnaire, including EQ-5D and EQ visual analogue scale (EQ-VAS). The primary outcomes were changes in EQ-5D and EQ-VAS from baseline to day 14 and day 90 after randomization. Results A total of 3219 patients with completed data on outcomes were enrolled, with median age of 63 years (interquartile range, 55–70) and 2,067 (64.2%) men. GDLM was associated with a significant decrease in scores of ED-5Q components (from 0 [no problem] to 3[extreme problem]), the mean difference between GDLM and placebo group was -0.14 for mobility, -0.11 for usual activities and self-care, -0.09 for pain/discomfort, and -0.34 for anxiety/depression on day 14, respectively. Similar results were observed on day 90. Additionally, there was statistically significant difference of changes in EQ-VAS between the GDLM group and the placebo group from baseline to day 14 (mean difference, 1.70; 95% confidence interval [CI], 0.78–2.62; P = 0.0003) and to day 90 after randomization (mean difference, 3.29; 95% CI, 2.37–4.22; P < 0.001). Conclusions In this analysis of Chinese patients with AIS, GDLM could improve the 14-day and 90-day quality of life compared with the placebo. Trial registration URL: https://www.clinicaltrials.gov . Unique identifier: NCT02526225. Registration Date: 2016–02-01.https://doi.org/10.1186/s12955-024-02315-1Acute ischemic strokeGinkgo diterpene lactone meglumineNeuroprotective drugsQuality of life
spellingShingle Xue Tian
Qin Xu
Xue Xia
Yijun Zhang
Xingquan Zhao
Anxin Wang
Effect of ginkgo diterpene lactone meglumine on the quality of life in patients with acute ischemic stroke
Health and Quality of Life Outcomes
Acute ischemic stroke
Ginkgo diterpene lactone meglumine
Neuroprotective drugs
Quality of life
title Effect of ginkgo diterpene lactone meglumine on the quality of life in patients with acute ischemic stroke
title_full Effect of ginkgo diterpene lactone meglumine on the quality of life in patients with acute ischemic stroke
title_fullStr Effect of ginkgo diterpene lactone meglumine on the quality of life in patients with acute ischemic stroke
title_full_unstemmed Effect of ginkgo diterpene lactone meglumine on the quality of life in patients with acute ischemic stroke
title_short Effect of ginkgo diterpene lactone meglumine on the quality of life in patients with acute ischemic stroke
title_sort effect of ginkgo diterpene lactone meglumine on the quality of life in patients with acute ischemic stroke
topic Acute ischemic stroke
Ginkgo diterpene lactone meglumine
Neuroprotective drugs
Quality of life
url https://doi.org/10.1186/s12955-024-02315-1
work_keys_str_mv AT xuetian effectofginkgoditerpenelactonemeglumineonthequalityoflifeinpatientswithacuteischemicstroke
AT qinxu effectofginkgoditerpenelactonemeglumineonthequalityoflifeinpatientswithacuteischemicstroke
AT xuexia effectofginkgoditerpenelactonemeglumineonthequalityoflifeinpatientswithacuteischemicstroke
AT yijunzhang effectofginkgoditerpenelactonemeglumineonthequalityoflifeinpatientswithacuteischemicstroke
AT xingquanzhao effectofginkgoditerpenelactonemeglumineonthequalityoflifeinpatientswithacuteischemicstroke
AT anxinwang effectofginkgoditerpenelactonemeglumineonthequalityoflifeinpatientswithacuteischemicstroke